W ith the use of endomyocardial biopsies, myocarditis has become recognized more widely.1-3 Virus infections initiate the disease although the suspected antigen is rarely isolated from patients with myocarditis. [4] [5] [6] [7] Current therapy for viral myocarditis is symptomatic and supportive because our understanding of the pathogenesis of myocarditis in humans is limited. For example, the efficacy of immunosuppressive therapy for viral myocarditis has been controversial, based upon both clinical8 9 and experimental studies. [10] [11] [12] [13] Recently, monoclonal antibody therapy has been explored in some diseases, focusing upon the etiologic factors. [14] [15] [16] Coxsackievirus B has been established as the predominant cause of viral myocarditis in humans. [5] [6] [7] The role of the immune system in acute coxsackievirus myocarditis and its sequelae remains uncertain.'-7Previous work of our laboratory showed the significance of T cells in the development and pathogenesis of murine viral myocarditis.17, '8 In this study, we investigated the effects of monoclonal antibodies against T cells in murine coxsackievirus B3 myocarditis.
Methods

Virus and Cell
Coxsackievirus B3 (CB3) (Nancy strain) (American Type Culture Collection, Rockville, Maryland) was used; the virus stock was prepared in cultures of VERO (kidney of African green monkey) cells in Eagle's minimum essential medium (EMEM). Virus suspensions were centrifuged after the cytopathic effect had developed. Virus stock had a titer of more than 10i plaque forming units (pfu) per 0.1 ml determined by plaque assay. Virus fluid was stored at -70o C until use. Viral titers were determined by plaque formation on VERO cell monolayers. Cells were suspended at a concentration of 1x106 in EMEM with 3% fetal calf serum (FCS) plus 100 gg/ml of penicillin and streptomycin in six-well plastic plates and were allowed to grow for 2 days at 370 C in 5% CO2.
Volumes (0.1 ml) of decimal dilutions of virus suspended in EMEM were absorbed to VERO cell monolayers for 60 minutes at 370 C in 5% CO2. After adsorption, the cells were overlaid with 3 ml medium containing 3% FCS and 1% methyl cellulose. After 2 days of incubation at 370 C in a humidified atmosphere containing 5% CO2, cells were fixed with acetic acid and methanol (at a ratio of 1: 3) and stained with crystal violet (1%); plaques were counted with an inverted microscope.
Monoclonal Antibodies
Rat In parallel with these experiments, uninfected 2-week-old male C3H/He mice received the same treatment as in experiment 1 [rat immunoglobulin (n=7), Lyt 1 (n=3), Lyt 2 (n=3), and Lyt 1 plus Lyt 2 (n=7) received groups], and they served as antibody-treated, uninfected controls. They were killed on days 10-14. The peripheral blood and spleen were processed for immunofluoresence study, and the thymus and spleen were frozen and processed for immunoperoxidase staining. Other organs were preserved for histologic study.
Earlier studies1416 had shown that the dosage of monoclonal antibodies used in this experiment is appropriate.
Immunostaining
These studies were performed to determine the in vivo effects of monoclonal antibodies upon the peripheral blood and lymphoid organs of uninfected controls. Immunofluorescence methods were similar to those described previously.17"18 In brief, the spleen was minced gently with a sterile stainless mesh. After mincing, the cell suspension was rapidly pipetted with a sterile Pasteur pipette into 20-25 ml Hanks' balanced salt solution (HBSS), filtered through nylon mesh to eliminate debris, and centrifuged at 1,500 rpm for 5 minutes. The cells were washed twice with HBSS. Peripheral blood (0.8-1.1 ml) was collected in heparin and washed twice with HBSS. The lymphocyte fractions of these samples were obtained by Ficoll gradient centrifugation; the suspensions were layered carefully on 4 ml Ficoll and centrifuged at 2,000 rpm for 15 minutes. Cell viability was determined by the trypan blue dye exclusion test. The cells were finally suspended at a concentration of 1 x 106 cells/ ml in RPMI-1640 media with 2.5% fetal calf serum and 0.1% NaN3. T cell subsets were stained using monoclonal rat anti-Lyt 1, rat anti-Lyt 2, and rat anti-Lyt 1 plus rat anti-Lyt 2 as the first layer of antibodies and fluorescein isothiocyanate-labeled rabbit anti-mouse immunoglobulin as the second. Fluorescein isothiocyanate-labeled anti-mouse immunoglobulin was diluted 10-fold, and rat monoclonal antibodies were diluted 10-fold. The cells were put into V-bottomed tubes and centrifuged at 1,500g for 3 minutes. After centrifugation, the cell pellet was suspended in 100 gl RPMI-1640 media with 2.5% fetal calf serum and 0.1% NaN3 on the first layer of antibodies. After incubation for 30 minutes at 40 C, the cells were washed three times and suspended in 1.0 ml RPMI-1640 media with 2.5% fetal calf serum and 0.1% NaN3. The percentage of positive fluorescent cells in each specimen was determined by the examination of at least 100 cells under a fluorescence microscope. The percentages of T-cell subsets were obtained by subtracting the percentage of positive cells stained with the second antibody from those obtained after staining with each monoclonal short axis'. and half of the heart was processed for Sections of thymus and spleen were inspected for cellularity and its depletion, those of lungs and liver for congestion, and kidney and pancreas for virus-induced lesions.
Virus Titers of Hearts
For infectivity assays, hearts were removed aseptically, and aliquots were weighed and homogenized in 2 ml EMEM. After centrifugation at 1,500g for 15 minutes at 40 C, supernatants (0.1 ml) were inoculated into VERO cell monolayers, and plaque assays were performed.
Serum Neutralizing Antibody Titers
Neutralizing antibody titers were determined in groups 1 and 4 in experiment 1, and in groups 5 and 8 in experiment 2, at the end of each experiment.
Blood was obtained under sterile conditions from the retro-orbital plexus, and the serum was inactivated at 560 C for 30 minutes. Each sample was titrated serially by determining the fourfold dilution in 5.0 ml EMEM supplemented with 3% FCS that protected VERO cell monolayers against a challenge of 100 pfu CB3 virus. Tubes were observed daily throughout a period of 7 days for the appearance of characteristic cytopathic effects.
Statistics
Differences between the control and treated survival curves were evaluated by the Kaplan-Meier method.'9 The differences of the percentages of lymphocyte subsets were examined by unpaired t tests. Virus titers of the heart and histologic scores were examined by one-way analysis of variance with multiple sample comparisons.20 Results 
Immunostaining
The results of the immunofluorescence study are listed in Table 1 . In both the peripheral blood and the spleen in animals treated with Lyt 1 plus Lyt 2 antibodies, the percentages of all the subsets were decreased compared with mice treated with rat immunoglobulin. In immunopathologic studies, uninfected mice treated with rat immunoglobulin (n=3) showed a positive reaction with a majority of thymocytes or cells of the T cell zone (paracortical area and periarterial sheath) in the spleen in the Lyt 1, Lyt 2, and Lyt 1 plus Lyt 2 stains. In contrast, uninfected mice treated with Lyt 
Uninfected Controls
None of the uninfected mice in the four groups (groups receiving rat immunoglobulin, Lyt 1, Lyt 2, and Lyt 1 plus Lyt 2) showed any histologic abnormalities in the heart, lung, liver, kidney, and pancreas.
Discussion
This study shows the beneficial effects of monoclonal antibody therapy against total T cells, but not for each T cell subset, consisting of partial protection against the development of CB3 virus myocarditis in the acute stage of illness, independent of myocardial virus replication.
The murine model of CB3 virus myocarditis shows a progression from viral infection to myocardial dysfunction: a biphasic disease process results when mice are infected with CB3 virus. During the acute phase, viral replication in the myocardium results in myocardial necrosis and inflammation. After the virus has been eliminated from the myocardium, a chronic inflammatory reaction may lead to progressive myocyte damage and hypertrophy, ventricular dilatation, and even heart failure. The chronic phase has been postulated to result from cell-mediated immune responses to a neoantigen that developed during the acute phase of the illness. [1] [2] [3] [4] [5] [6] [7] To clarify the immune mechanisms in myocarditis in CB3 virus murine models, we already showed the different kinetics of lymphocyte subsets between the peripheral blood and the heart, their serial changes in the course of the disease, and the significance of myocardial Thy 1.2+ (pan T) and Lyt 1+ (helper/inducer T) cells in the development of myocarditis.17 Similar results were also shown in encephalomyocarditis virus-induced murine myo- carditis models.'8 These data led us to the present study of the effects of monoclonal antibodies upon murine CB3 virus myocarditis.
In experiment 1 (viremic stage) of this study, significant improvement of survival and reduction in cellular infiltration were shown in group 4, but not in groups 2 and 3, compared with controls. The lack of change in myocardial necrosis or calcification in group 4 may be related to the longer survival rate; indeed, nine mice survived until day 14. Murine myocardial calcification is accompanied by cell necrosis and increases with time. In experiment 2 (aviremic stage), significant improvement of survival and a decrease in cellular infiltration and necrosis were seen in group 8.
With regard to the assigned functions of each murine lymphocyte subset, the Lyt 1+ and Lyt 2+ subset (Lyt 1+, 23+ subset) is thought to be the immature T cells and precursor of other T cell subsets; it has been shown to be an alloreactive and syngeneic cytotoxic lymphocyte subset in addition to the Lyt 1-and Lyt 2+ subset (Lyt 1-, 23+ against T cells does not suppress neutralizing antibody formation in the host. Future work should address the question whether the administration of monoclonal antibodies affects the population of myocardial infiltrating lymphocytes in each group. Therapy for clinical viral myocarditis has remained symptomatic and supportive, and specific treatment has not been available. The use of immunosuppressive agents,8-13 including cyclosporines, is still controversial, and clinicians have to recognize the side effects of these agents. Antiviral agents, such as ribavirin23,24 or interferon,25,26 can be used only as long as the virus is present in the host; in clinical settings, the likelihood is small. Thus, monoclonal antibody therapy against pan T cells may be useful for the treatment of patients with myocarditis, irrespective of the presence of the virus, even though its effect may be only partial. Further investigations in different strains of mice infected with this and other strains of coxsackievirus are indicated, with ultimate aim to explore this therapeutic approach in early cases of identified coxsackievirus myocarditis in humans.
